These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15478544)

  • 1. The role of improved water quality on inflammatory markers in patients undergoing regular dialysis.
    Rahmati MA; Homel P; Hoenich NA; Levin R; Kaysen GA; Levin NW
    Int J Artif Organs; 2004 Aug; 27(8):723-7. PubMed ID: 15478544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort.
    Kim T; Rhee CM; Streja E; Obi Y; Brunelli SM; Kovesdy CP; Kalantar-Zadeh K
    Nephrol Dial Transplant; 2017 Feb; 32(2):370-377. PubMed ID: 28186572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anemia in peritoneal dialysis patients].
    Lausević M; Nesić V; Jovanović N; Stojimirović B
    Srp Arh Celok Lek; 2006; 134(3-4):133-7. PubMed ID: 16915754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients.
    Tsuchiya K; Okano H; Teramura M; Iwamoto Y; Yamashita N; Suda A; Shimada K; Nihei H; Ando M
    Clin Nephrol; 2003 Feb; 59(2):115-23. PubMed ID: 12608554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.
    Gupta A; Amin NB; Besarab A; Vogel SE; Divine GW; Yee J; Anandan JV
    Kidney Int; 1999 May; 55(5):1891-8. PubMed ID: 10231452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of reticulocyte hemoglobin equivalent with traditional markers of iron and erythropoiesis in pediatric dialysis.
    Davidkova S; Prestidge TD; Reed PW; Kara T; Wong W; Prestidge C
    Pediatr Nephrol; 2016 May; 31(5):819-26. PubMed ID: 26667237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
    Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
    J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
    Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
    Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
    Park L; Uhthoff T; Tierney M; Nadler S
    Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein as an outcome predictor for maintenance hemodialysis patients.
    Owen WF; Lowrie EG
    Kidney Int; 1998 Aug; 54(2):627-36. PubMed ID: 9690231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of erythropoietin responsiveness in chronic hemodialysis patients.
    Tonelli M; Blake PG; Muirhead N
    ASAIO J; 2001; 47(1):82-5. PubMed ID: 11199321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients.
    Sezer S; Tutal E; Bilgic A; Ozdemir FN; Haberal M
    Transplant Proc; 2007; 39(1):40-4. PubMed ID: 17275471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
    Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
    Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.